OCT 29, 2019 8:00 AM PDT

Multi-omics Approach to Understanding PD-L1 Resistance in Cancer

Sponsored by: Sony Biotechnology
C.E. Credits: P.A.C.E. CE Florida CE
Speakers
  • Instructor in Medicine and the Director of the Translational Cancer Immunology lab - Massachusetts General Hospital Cancer Center
    Biography
      Moshe Sade Feldman (PhD) is an Instructor in Medicine and the Director of the Translational Cancer Immunology lab at Massachusetts General Hospital Cancer Center. His research focus is the development of new, unbiased strategies to understand basic immune processes and immune-mediated diseases, with an emphasis on the immune system and personal medicine.
    • Assistant Professor and Member of the Faculty of Medicine - Massachusetts General Hospital Cancer Center
      Biography
        Russell Jenkins (MD, PhD) is an Assistant Professor and Member of the Faculty of Medicine, Massachusetts General Hospital Cancer Center. His research focus is understanding why immunotherapy works for some patients and not others. The Jenkins laboratory uses sophisticated tools such as 3-dimensional cultures of patients' tumors to investigate the complex and dynamic interactions between cancer cells and the immune system.

      Abstract

      DATE: October 29, 2019

      TIME:  8:00am PDT

      Although immune-based therapies targeting the inhibitory receptors (PD-L1, PD1, and CTLA4) are proven to be effective to treat cancer, some patients do not respond, or stop responding within the first year of therapy. Identifying the underlying mechanisms associated with these variable response rates remains an important open research challenge in clinical oncology.

      Join this free webinar to learn how researchers are integrating cell sorting, RNA sequencing, ex-vivo phenotype profiling, and patient-derived xenografts to study the mechanisms of PD-L1 resistance in cancer.

       

      Who Should Attend:

      Researchers who want to integrate a multi-omics approach in their clinical studies on immune checkpoint inhibitor resistance will gain valuable insights. In addition, the webinar will benefit those who want to learn about new technologies for isolating and profiling tumor cells. 

       

      Learning Objectives:

      • Review how a multi-omics approach can be used to study the resistance mechanisms to therapies targeting immune checkpoint inhibitors.

      • Evaluate how new clinical research tools can uncover complexities of tumors and their ecosystems.  

       

      Webinars will be available for unlimited on-demand viewing after live event.

       

      LabRoots is approved as a provider of continuing education programs in the clinical laboratory sciences by the ASCLS P.A.C.E. ® Program. By attending this webinar, you can earn 1 Continuing Education credit once you have viewed the webinar in its entirety.


      Show Resources
      Show Resources
      Attendees
      • See more
      Connect with us